Using demographics of patients to inform treatment of shigellosis in England

Lewis C. E. Mason, Daniel Richardson, Hannah Charles, Ian Simms, Holly Mitchell, Rohini Manuel, Gauri Godbole, Claire Jenkins, Kate S. Baker

The Lancet Microbe · 2024 · 18 citations · 6 references

DOIFull text

Open access

Concepts

Abstract

Shigellosis, caused by bacteria of the genus Shigella, is a diarrhoeal disease transmitted by the faecal–oral route.1 Rapid increases in the prevalence of extensively drug-resistant (XDR) Shigella isolates—also known as triple-resistant due to resistance to fluoroquinolones, third-generation cephalosporins, and azithromycin—during the final quarter of 2021 and the first quarter of 2022 in Europe, Northern America, and Australia have highlighted the urgent need to develop new antimicrobials and vaccines targeting high-priority Shigella spp.

References

6